期刊文献+

华法林在基层医院51例老年病人中的应用

下载PDF
导出
摘要 目的了解华法林在基层医院的应用情况,增加华法林基层医院的应用。方法本文收集2010年1月至2013年12月我院门诊和住院病人51例,男27例、女24例,年龄60-91岁,平均71.4岁,>75岁11例,华法林疗程3个月-5年。给予华法林2.5mg/日(1片),每晚6时口服,开始3-4天查INR一次,7-8天INR未达标者,华法林增加到3.75mg/日(1片半)。结果华法林维持用量0.125-5mg/日。达到INR目标值的时间6-15天。49例(96.1%)INR达到目标值。4例(7.8%)病人在用华法林的过程中3-6个月时出现不明原因的INR数值的波动,波动范围1.4-4.3,有36%的病人在2个月后不能按时来医院复查INR。3例轻微出血,1例停药,死亡2例。华法林用于预防心房颤动脑梗塞比例为2.0%。结论在充分的沟通后,定期复查INR,华法林能在基层医院的老年病人中安全应用。
出处 《心血管病防治知识(学术版)》 2015年第4期12-13,共2页 Prevention and Treatment of Cardiovascular Disease
  • 相关文献

参考文献3

二级参考文献27

  • 1[9]Poli D,Antonucei E,Cecchi E,et al.Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation:the role of homocysteine[J].Stroke,2005,36(10):2159-2163.
  • 2[10]Fang MC,Singer DE,Chang Y,et al.Gender differences in the risk of ischemie stroke and peripheral embolism inatrial fibrillation:the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study[J].Circulation,2005,112(12):1687-1691.
  • 3[11]Lip GY,Hart RG,Conway DS.Antithrombotic therapy for atrial fibrillation[J].BMJ,2002,325 (7371):1022-1025.
  • 4[12]Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC2006 guidelines for the management of patients with atrial fibrillation-executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)[J].J Am Coil Cardiol,2006,48(4):854906.
  • 5[13]Go AS,Fang MC,Singer DE.Antithrombotic therapy for stroke prevention in atrial fibrillation[J].Prog Cardiovasc Dis,2005,48(2):108-124.
  • 6[14]Economides Munoz C,Singh BN.Antithrombotic therapies for stroke prevention in atrial fibrillation[J].Minerva Cardioangiol,2004,52 (2):125-139.
  • 7[15]O'Donnell M,Weitz JI.Emerging therapies for stroke prevention in atrial fibrillation[J].Eur Heart J,2005,7(Suppl C):C19-C27.
  • 8[16]Ostermayer SH,Reisman M,Kramer PH,et al.Percutaneous left atrial appendage transcatheter occlusion(PLAATO system)to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation:results from the international multi-center feasibility trials[J].J Am CoilCardiol,2005,46(1):9-14.
  • 9[17]Sievert H,Lesh MD,Trepels T,et al.Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation:early clinical experience[J].Circulation,2002,105(16):1887-1889.
  • 10[18]Gurewich V.Ximelagatran-promises and concerns[J].JAMA,2005,293(6):736-739.

共引文献1520

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部